Choroidal melanoma is the most common primary intraocular malignancy in adults. Alternative treatment modalities have been proposed in recent years including enucleation, local resection ...

Aura Biosciences (AURA) has reported its Q4 and full-year 2024 financial results, prompting an ongoing decline in shares despite showing ...

Aura's clinical pipeline continues to advance with the active enrollment in the Phase 3 CoMpass trial for early-stage choroidal melanoma and the initiation of a Phase 2 trial for metastases to the ...

Positive Phase 1 Trial Data in Non-Muscle Invasive Bladder Cancer (NMIBC) Presented at the 40th Annual European Association of Urology Congress; ...

Researchers have uncovered a stealth survival strategy that melanoma cells use to evade targeted therapy, offering a promising new approach to improving treatment outcomes.

12 after the company announced encouraging data from a phase II study evaluating its lead candidate, bel-sar (AU-011), to treat early-stage choroidal melanoma (CM) in the first-line setting.

No writing assistance was utilized in the production of this manuscript. Choroidal melanoma is the most common primary intraocular malignant tumor in adults and results in metastatic death in up ...

The data presented from the Phase 2 trial in early-stage choroidal melanoma and the Phase 1 trial in NMIBC demonstrated bel-sar’s potential as a front-line treatment option across multiple tumor ...